InvestorsHub Logo
Followers 117
Posts 16800
Boards Moderated 3
Alias Born 10/02/2003

Re: nilremerlin post# 224972

Friday, 06/26/2020 4:47:50 PM

Friday, June 26, 2020 4:47:50 PM

Post# of 238141
Kannalife is doing this also.announced in April-.The Company chose Atopidine™ as the trademark for Limonenyldihydroxybenzyl Ethoxycarbonyl Azetidine (“LEA”), the International Nomenclature of Cosmetic Ingredient (INCI) assigned name for the Company’s patented monotherapeutic compound KLS-13022.

In pre-clinical testing, Atopidine™ was shown to decrease inflammatory cytokine (TNFa, Il-1ß, CXCL5 and IL-8) levels at concentrations 50 times less than toxic levels. Atopidine™ was effective in an in vitro photoaging experiment with anti-inflammatory action based on IL-6 inhibition against UVA irradiation in cultured human dermal fibroblasts cells. IL-6 is a cytokine (an immune system signaling molecule) that has been shown to promote inflammation and currently among the targets believed to be creating the cytokine storm in SARS-CoA-2 (“COVID-19”)..https://www.kannalife.com/kannalife-inc-receives-notice-of-allowance-from-uspto-for-trademark-of-atopidine/